Fluoropharma Medical (OTCMKTS:FPMI) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Volatility and Risk
Fluoropharma Medical has a beta of 3.76, suggesting that its share price is 276% more volatile than the S&P 500. Comparatively, Quidel has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
This table compares Fluoropharma Medical and Quidel’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fluoropharma Medical||N/A||N/A||-$2.04 million||N/A||N/A|
|Quidel||$522.28 million||4.74||$74.18 million||$2.82||22.09|
Quidel has higher revenue and earnings than Fluoropharma Medical.
This is a summary of current ratings and target prices for Fluoropharma Medical and Quidel, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Quidel has a consensus price target of $73.60, indicating a potential upside of 18.18%. Given Quidel’s higher probable upside, analysts clearly believe Quidel is more favorable than Fluoropharma Medical.
Institutional and Insider Ownership
92.9% of Quidel shares are held by institutional investors. 36.9% of Fluoropharma Medical shares are held by insiders. Comparatively, 16.7% of Quidel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Fluoropharma Medical and Quidel’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Quidel beats Fluoropharma Medical on 9 of the 11 factors compared between the two stocks.
About Fluoropharma Medical
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Receive News & Ratings for Fluoropharma Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluoropharma Medical and related companies with MarketBeat.com's FREE daily email newsletter.